NCT06671912 2026-03-04
LoTam
Alliance for Clinical Trials in Oncology
Phase 3 Suspended
Clinical Trials
7 trialsNCT04973930 2025-05-13
IPT
New York State Psychiatric Institute
Phase 3 Suspended
NCT02037529 2024-08-20
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
Academic and Community Cancer Research United
Phase 3 Suspended
NCT05503108 2023-11-22
DIRECT-2
Leiden University Medical Center
Phase 3 Suspended
NCT03002103 2023-04-26
A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer
SynCore Biotechnology Co., Ltd.
Phase 3 Suspended
NCT03777579 2019-08-08
A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Suspended
NCT00002696 2013-08-02
Combination Chemotherapy in Treating Women With Stage III Breast Cancer
National Cancer Institute (NCI)
Phase 3 Suspended